From the Department of Psychology, University of California, Los Angeles, Los Angeles, CA (LRM, LAR); Los Angeles County Department of Public Health, Los Angeles, CA (BH); Friends Research Institute, Cerritos, CA (BH, TCF, LR, BL, NM, TD); Los Angeles County Department of Health Services, Los Angeles, CA (TCF, HKB, SH); Department of Internal Medicine, Charles R. Drew University, Los Angeles, CA (TCF, MLL); Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA (MLL); Brain Research Institute, University of California, Los Angeles, Los Angeles, CA (LAR); and Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA (LAR).
J Addict Med. 2023;17(6):677-684. doi: 10.1097/ADM.0000000000001211. Epub 2023 Aug 18.
Although public efforts to reduce tobacco use have been successful, millions of US adults currently smoke tobacco. Reducing the public health burden of tobacco use disorder (TUD) and eliminating disparities experienced by underresourced communities requires increased accessibility to services. The goal of this study was to assess whether prescriptions for evidence-based medications for tobacco treatment showed steeper growth rates among community health clinics providing specialty TUD services as compared with treatment as usual.
Clinic-wide data on prescriptions for smoking cessation pharmacotherapy at 18 primary care or mental health community clinics operated by Los Angeles County were retrieved for 4 years of an ongoing implementation trial. Specialty services included behavioral counseling and medications for tobacco treatment. Descriptive statistics characterized prescriptions rates across clinics and time. Analyses compared the slopes of the changes between intervention groups across time for primary care and mental health sites.
Within primary care clinics, the most commonly prescribed smoking cessation medications were nicotine patches, nicotine gum, and varenicline. Throughout the trial, all clinics displayed increased rates of prescribing smoking cessation medications. Analytic results supported overall steeper increases in prescription rates for these medications among clinics randomized to specialty services versus treatment as usual within primary care ( P = 0.020) and mental health sites ( P = 0.004).
This work provides support for the effectiveness of community-based implementation interventions that promote prescribing smoking cessation medications with the potential to reduce health disparities among communities at greater risk for TUD and its consequences.
尽管公众在减少烟草使用方面已经取得了成功,但目前仍有数百万美国成年人吸烟。要减轻烟草使用障碍(TUD)对公众健康的负担并消除资源匮乏社区所面临的差异,就需要提高服务的可及性。本研究旨在评估为 TUD 提供专业服务的社区卫生诊所开具基于证据的烟草治疗药物处方的增长率是否高于常规治疗。
检索了洛杉矶县 18 家初级保健或心理健康社区诊所开展的一项正在进行的实施试验的 4 年期间内,所有戒烟药物治疗的处方数据。专业服务包括行为咨询和烟草治疗药物。描述性统计方法描述了各诊所和各时段的处方率。分析比较了常规治疗和心理健康诊所内干预组随时间变化的变化斜率。
在初级保健诊所中,最常开的戒烟药物是尼古丁贴片、尼古丁口香糖和伐尼克兰。在整个试验期间,所有诊所都增加了开具戒烟药物的处方率。分析结果支持在常规治疗中随机分配到专业服务的诊所,其戒烟药物处方率总体上呈上升趋势(P=0.020),在心理健康诊所也是如此(P=0.004)。
这项工作为基于社区的实施干预措施的有效性提供了支持,这些干预措施可以促进开具戒烟药物处方,从而有可能减少 TUD 及其后果风险较高的社区的健康差异。